SBIR/STTR Research Award

Developing a new AAV-based tool for targeted gene therapy against hearing loss

Award identifier 67572216ce0cde2492625d7879e20987d4b0ac1ddaae87ec02887c969a65267eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,700

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GATEWAY BIOTECHNOLOGY, INC.
Proposal award date
2018-08-01
Contract end date
2019-07-31
UEI
XDDXGL6JRRD9
Solicitation number
PA17-302
Topic code
NIDCD

Research abstract

Project Summary Gene therapy mediated by recombinant adeno associated virusrAAVvectors has been clinically successful for the treatment of certain eye diseasesHoweverno successful clinical outcomes exist to treat hearing lossSince the cochlea is enclosed mostly within the temporal bonelocal viral gene delivery can itself cause hearing lossIn additionthe elaborate structure and exquisite function of the inner ear require coordinated action of diverse inner ear cell typesincluding the sensory hair cellssupporting cellsspiral ganglion neuronsand stria vascularisNo current rAAV gene delivery can specifically target spiral ganglion neuronswhich are the only neuron type to carry auditory information from hair cells to central auditory systemThereforeit would be ideal if rAAVs can target spiral ganglion neurons after a systemic injectionAAVhas recently been found to be able to cross the blood brain barrier after a systemic injectionBased on our previous studies and discussions with potential consumersin this projectwe proposed to make two productsone new AAVbased library with random sequences in Cap open reading framesandat least one rAAV specifically targeting spiral ganglion neuronsTo achieve these goalswe have set up specific milestones in our two aimsIn Aimwe will make a novel AAVbased vector in which the expression of capsid proteins is coupledbut not fusedto green fluorescent proteinand then we will make random mutagenesis of the Cap gene to generation of the rAAV viral libraryIn Aimour collaborators will inject this rAAV viral library into the mouse tail vein and isolate specific rAAV DNA from spiral ganglion neurons two weeks post injectionThe process will be iterated to enhance the targeting specificity of rAAV capsid protein variants to SGNsThe novel parts of our technology areusing a strategy to co express GFP with rAAV capsid proteinswhich allows direct recovery of cell specific rAAV Cap open reading framefocusing on AAVwhich can cross the blood brain barrier after a systemic injectionandworking with our collaboratorsspiral ganglion neurons will be targeted without requirement of prepurification and pre labellingIf successfulthis project will not only establish a neuronal specific targeting tool for cochlear gene therapybut also provide an rAAV library for screening other rAAVs able to target other types of cells in the auditory systemThusthis project will not only lead to a new rAAV vector to treat hearing lossbut also provide a new rAAV library for the research field PROJECT NARRATIVE The work in this proposal focuses on the development of an rAAV based tool for gene therapy against hearing lossIf successfulthis project will not only lead to a new rAAV vector to treat hearing lossbut also provide a new rAAV library for the research field

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $6,645,112. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.